A Review of Chemotherapeutic Approaches to the treatment of Cryptosporidium

Cryptosporidium: From Molecules to Disease

Volumn , Issue , 2003, Pages 395-403

  Armson, A ^a   Reynoldson, J A ^a   Thompson, R C A ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 25144449077     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044451351-9/50062-8     Document Type: Chapter

References (57)

1. Armson A., Meloni B.P., Reynoldson J.A., Thompson R.C.A. Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method. FEMS Microbiol. Lett. 1999, 178:227-233.
2. Armson A., Sargent K., MacDonald L.M., Thompson R.C.A., Reynoldson J.A. A comparison of the in vitro and in vivo effects of two dinitroanilines against Cryptosporidium parvum in neonatal mice. FEMS Immunol. Med. Microbiol. 1999, 26:109-113.
3. Armson A., Kamau S.W., Grimm F., Reynoldson J.A., Best W.M., MacDonald L.M., Thompson R.C.A. A comparison of the effects of a benzimidazole and the dinitroanilines against Leishmania infantum. Acta Trop. 1999, 73:303-311.
4. Armson A., Menon K., O'Hara A., MacDonald L.M., Read C.M., Sargent K., Thompson R.C.A., Reynoldson J.A. Efficacy of oryzalin and associated histological changes in Cryptosporidium-infected neonatal rats. Parasitology 2002, 125:113-117.
5. Armson, A., MacDonald, L.M., Thompson, R.C.A., Reynoldson, J.A. Inhibition of two plastid pathways in Cryptosporidium parvum cattle strain (in preparation).
6. Arrowood M.J., Jaynes J.M., Healey M.C. In vitro activities of lytic peptides against the sporozoites of Cryptosporidium parvum. Antimicrob. Agents Chemo. 1991, 35:224-227.
7. Arrowood M.J., Mead J.R., Xie L.T., You X.D. In vitro anticryptosporidial activity of dinitroaniline herbicides. FEMS. Microbiol. Lett. 1996, 136:245-249.
8. Benbow J.W., Bernberg E.L., Korda A., Mead J.R. Synthesis and evaluation of dinitroanilines for treatment of cryptosporidiosis. Antimicrob. Agents Chemother. 1998, 42:339-343.
9. Blagburn B.L., Soave R. Prophylaxis and chemotherapy: human and animal. Cryptosporidium and Cryptosporidiosis 1997, CRC Press, New York. R. Fayer (Ed.).
10. Cabello R.R., Guerrero L.R., Garcia M.R.M., Cruz A.G. Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico. Trans. Roy. Soc. Trop. Med. Hyg. 1997, 91:701-703.
11. Callahan H.L., Kelley C., Pereira T., Grogl M. Microtubule Inhibitors: Structure-activity analyses suggest rational models to identify potentially active compounds. Antimicrob. Agents Chemother. 1996, 40:947-952.
12. Cama V.A., Marshall M.M., Shubitz L.F., Ortega Y.R., Sterling C.R. Treatment of acute and chronic Cryptosporidium parvum infections in mice using clarithromycin and 14-OH clarithromycin. J. Euk. Microbiol. 1994, 41:25S.
13. Carreno R.A., Martin D.S., Barta J.R. Cryptosporidium is more closely related to gregarines than to coccidia as shown by phylogenetic analysis of apicomplexan parasites inferred using small-subunit ribosomal RNA gene sequences. Parasitol. Res. 1999, 85:899-904.
14. Chan M.-Y., Grogl M., Chen C.-C., Bienen E.J., Fong D. Herbicides to curb human parasitic infections: in vitro and in vivo effects of trifluralin on the trypanosomatid protozoans. Proc. Nat. Acad. Sci. USA 1993, 90:5657-5661.
15. Doumbo O., Rossignol J.F., Pichard E., Traore H.A., Dembele M., Diakite M., Traore F., Diallo D.A. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with aquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 1997, 56:637-639.
16. Favennec L. Physiopathologic and therapeutic studies in in vitro and in vivo models of Cryptosporidium parvum infection. J. Euk. Microbiol. 1997, 44:69S-70S.
17. Fayer R., Ellis W. Paromomycin is effective as a prophylaxis for Cryptosporidiosis in dairy calves. J. Parasitol. 1993, 79:771-774.
18. Fayer R., Fetterer R. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice. J. Parasitol. 1995, 81:794-795.
19. Griffiths J.K., Moore R., Dooley S., Keusch G.T., Tzipori S. Cryptosporidium parvum infection of Caco-2 cell monolayers induces an apical monolayer defect, selectively increases transmonolayer permeability and causes epitheleial cell death. Inf. Immun. 1994, 62:4506-4514.
20. Hijjawi N.S., Meloni B.P., Morgan U.M., Olson M.E., Thompson R.C.A. Successful in vitro cultivation of Cryptosporidium andersoni with evidence for the existence of novel extracellular stages in the Cryptosporidium life cycle. Int. J. Parasitol. 2002, 32:1719-1726.
21. Katiyar S.K., Gordon V.R., McLaughlin G.L., Edlind T.D. Antiprotozoal activities of benzimidazoles and correlations with β-tubulin sequence. Antimicrob. Agents Chemother. 1994, 38:2086-2090.
22. Keithly J.S., Zhu G., Upton S.J., Woods K.M., Martinez M.P., Yarlett N. Polyamine biosynthesis in Cryptosporidium parvum and its implications for chemotherapy. Molec. Biochem. Parasitol. 1997, 88:35-42.
23. Leitch G.J., He Q. Putative anticryptosporidial agents tested with an immunodeficient mouse model. Antimicrob. Agents Chemother. 1994, 38:865-867.
24. Lemeteil D., Roussel F., Favennec L. Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model. J. Infect. Dis. 1993, 167:766-768.
25. Lindsay D.S. Laboratory models of cryptosporidiosis. Cryptosporidium and cryptosporidiosis 1997, CRC Press, New York. R. Fayer (Ed.).
26. MacDonald L.M., Sargent K., Armson A., Thompson R.C.A., Reynoldson J.A. The development of a realtime quantitative-PCR method for characterisation of a Cryptosporidium parvum in vitro culturing system and assessment of drug efficacy. Molecul. Biochem. Parasitol. 2002, 121:279-282.
27. Marechal E., Cesbron-Delauw M.F. The apicoplast: a new member of the plastid family. Trends Plant Sci. 2001, 6:200-204.
28. Mead J.R. Cryptosporidium research 2001: Workshop Summary. J Euk Microbiol 2001, 1(suppl.):15s-16s.
29. Mead J. Cryptosporidiosis and the challenges of chemotherapy. Drug Resist. Updates. 2002, 5:47-57.
30. Mead J.R., You X., Pharr J.E., Belenkaya Y., Arrowood M.J., Fallon M.T., Schinazi R.F. Evaluation of maduramycin and alborixin in a SCID mouse model of chronic cryptosporidiosis. Antimicrob. Agents Chemother. 1995, 39:854-858.
31. Meloni B.P., Thompson R.C.A. Simplified methods for obtaining purified oocysts from mice and for growing Cryptosporidium parvum in vitro. J. Parasitol. 1996, 82:757-762.
32. Meloni B.P., Thompson R.C.A., Reynoldson J.A., Seville P. Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans. Roy. Soc. Trop. Med. Hyg. 1990, 84:375-379.
33. Moore D., Waters W.R., Wannemuehler M.J., Harp J.A. Treatment with agmatine inhibits Cryptosporidium parvum infection in infant mice. J. Parasitol. 2001, 211-213.
34. Morgan U.M., Reynoldson J.A., Thompson R.C.A. Activities of several benzimidazoles and tubulin inhibitors against Giardia spp. in vitro. Antimicrob. Agents Chemother. 1993, 37:328-331.
35. Moss D., Arrowood M. Quantification of Cryptosporidium parvum oocysts in mouse fecal specimens using immunomagnetic particles and two-colour flow cytometry. J. Parasitol. 2001, 87:406-412.
36. Nelson R., Rosowsky A. Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of Cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations. Antimicro. Agents Chemo. 2001, 45:3293-3303.
37. Rehg J.E. Activity of azithromycin against Cryptosporidia in immunosuppressed rats. J. Infect. Dis. 1991, 163:1293-1296.
38. Rehg J.E. Anticryptosporidial activity of lasalocid and other ionophorous antibiotics in immunosuppressed rats. J. Infect. Dis. 1993, 168:1566-1569.
39. Rehg J.E. A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats. J. Infect. Dis. 1994, 170:934-938.
40. Roberts C.W., Roberts F., Lyons R.E., Kirisits M.J., Mui E.J., Finnerty J., Johnson J.J., Ferguson D.J., Coggins J.R., Krell T., Coombs G.H., Milhoue W.K., Kyle D.E., Tzipori S., Barnwell J., Dame J.B., Carlton J., McLeod R. The shikimate pathway and its branches in apicomplexan parasites. J. Infect. Dis. 2002, 185:S25-S36.
41. Roberts-Thompson I.C., Stevens D.P., Mahmoud A.A.F., Warren K.S. Giardiasis in the mouse: an animal model. Gastroenterology 1976, 71:57-61.
42. Rohlman S., Kuhls V.C., Mosier D.A., Crawford D.L., Hawkins D.R., Abrams V.L. Therapy with atovaquone for Cryptosporidium parvum infection in neonatal severe combined immunodefficiency mice. J. Infect. Dis. 1993, 168:258-260.
43. Ruest N., Couture Y., Faubert G.M., Girard C. Morphological changes in the jejunum of calves naturally infected with Giardia spp. and Cryptosporidium spp. Vet. Parasitol. 1997, 69:177-186.
44. Sreter T., Szell Z., Varga I. Anticryptosporidial prophylactic efficacy of enrofloxacin and paromomycin in chickens. J. Parasitol 2002, 88:209-211.
45. Tetley L., Brown S.M.A., McDonald V., Coombs G.H. Ultrastructural analysis of the sporozoite of Cryptosporidium parvum. Microbiology 1998, 144:3249-3255.
46. Tzipori S. Cryptosporidiosis: Laboratory Investigations and Chemotherapy. Adv. Parasitol. 1998, 40:187-221.
47. Tzipori S., Campbell I., Angus T. The therapeutic effect of 16 antimicrobial agents on Cryptosporidium infection in mice. Aust. J. Exp. Biol. Med. Sc. 1982, 60:187-190.
48. Tzipori S., Rand W., Griffiths J.K., Widmer G., Crabb J. Model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin. Diag. Lab. Immunol. 1994, 1:450-463.
49. Upton S.J., Tilley M., Brillhart D.B. Comparative development of Cryptosporidium parvum (Apicomplexa) in 11 continuous host cell lines. FEMS Microbiol. Lett. 1994, 118:233-236.
50. Upton S.J., Tilley M., Brillhart D.B. Comparative development of Cryptosporidium parvum in MDBK and HCT-8 cells under select atmospheres. Biomed. Lett. 1994, 49:265-271.
51. Upton S.J., Tilley M., Nesterenko M.V., Brillhart D.B. A simple and reliable method of producing in vitro infections of Cryptosporidium parvum (Apicomplexa). FEMS Microbiol. Lett. 1994, 118:45-50.
52. Upton S.J., Tilley M., Brillhart D.B. Effects of select medium supplements on in vitro development of Cryptosporidium parvum in HCT-8 cells. J. Clin. Microbiol. 1995, 33:371-375.
53. Woods K.M., Nesterenko M.V., Upton S.J. Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. FEMS Microbiol. Lett. 1995, 128:89-94.
54. Woods K.M., Nesterenko M.V., Upton S.J. Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro. Ann. Trop. Med. Parasitol. 1996, 90:603-615.
55. Yang S., Healey M.C. The immunosuppresive effects of dexamethasone administered in drinking water to C57BL/6N mice infected with Cryptosporidium parvum. J. Parasitol. 1993, 79:626-630.
56. Zhu G., Marchewka M.J., Keithly J.S. Cryptosporidium parvum appears to lack a plastid geneome. Microbiology 2000, 146:315-321.
57. Zumla A., Croft S.L. Chemotherapy and immunity in opportunistic parasitic infections in AIDS. Parasitology 1992, 105:S93-S101.